COVID-19 Therapeutic Alert: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)

MHRA Central Alerting System team Coronavirus alerts banner

COVID-19 Therapeutic Alert: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)

The REMAP-CAP trial has reported a finding of survival and time to recovery benefits for tocilizumab or sarilumab, over and above current standard of care (including corticosteroids), in the immune modulation therapy domain of the REMAP-CAP platform trial.

Work is now underway to develop a UK clinical commissioning policy for tocilizumab and sarilumab, which will be based on a NICE review of the available research evidence. The policy will replace the Interim Position Statement.

This alert sets out immediate steps which NHS acute trusts / health boards are asked to take to support treatment of patients admitted to intensive care with COVID-19.

Access the alert

Thank you,
Central Alerting System team, MHRA

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to safetyalerts@subscriptions.mhra.gov.uk

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.